Biotech Catalyst Daily · Blog
Evergreen reference articles. Published weekly.
- 2026-04-19 Decoding Phase 3 Clinical Trial Results: A Guide for Investors Understanding what matters in Phase 3 readouts can guide investment decisions.
- 2026-04-29 Understanding Orphan Drug Designation: Mechanics and Strategic Use Exploring the mechanics and strategic benefits of orphan drug designation in biotech and pharma.
- 2026-04-22 How to Interpret a Phase 3 Topline Readout in the First 20 Minutes An analyst-grade guide to reading Phase 3 topline press releases. Primary endpoints, statistical gotchas, secondary signals, and FDA review context — in the first 20 minutes after the print.
- 2026-04-22 Reading an FDA AdCom: Voting Outcomes, Base Rates, and the Trade After the Vote How to interpret FDA Advisory Committee votes — what they actually decide, historical FDA follow rates, committee composition, and the AdCom fade trading pattern.
- 2026-05-20 Decoding FDA Language: Fast Track, Breakthrough, Priority Review Understanding FDA's expedited programs for drug approval.
- 2026-05-13 Navigating the Complete Response Letter: A Strategic Playbook An authoritative guide to understanding and responding to FDA Complete Response Letters.
- 2026-04-19 Decoding the PDUFA Decision Process A comprehensive guide to understanding PDUFA decisions in drug approval.
- 2026-04-22 Inside FDA Advisory Committee Meetings: A Comprehensive Guide Understand the mechanics and significance of FDA advisory committee meetings.
- 2026-05-06 Navigating Accelerated Approval and the Conversion Challenge Understanding the mechanics and implications of accelerated approval in drug development.